{
    "id": 163,
    "fullName": "EGFR wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type EGFR indicates that no mutation has been detected within the EGFR gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "wild-type",
    "createDate": "03/11/2014",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12877,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, compared to Taxotere (docetaxel), treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in EGFR wild-type (HR=0.67, P<0.001) but not EGFR mutant (HR=1.11, P=0.54) non-small cell lung carcinoma patients, and there was a statistically significant treatment-EGFR mutation interaction (p=0.005) (PMID: 29270615).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10827,
                    "pubMedId": 29270615,
                    "title": "Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29270615"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7584,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 did not inhibit proliferation of transformed cells harboring wild type EGFR in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12879,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, compared to Taxotere (docetaxel), treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in EGFR wild-type (HR=0.67, P<0.001) but not EGFR mutant (HR=1.11, P=0.54) non-small cell lung carcinoma patients, and there was a statistically significant treatment-EGFR mutation interaction (p=0.005) (PMID: 29270615).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10827,
                    "pubMedId": 29270615,
                    "title": "Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29270615"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12995,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Taxotere (docetaxel) is included in guidelines for EGFR wild-type non-small cell lung cancer patients (NCCN.org).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 720,
                "therapyName": "Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9742,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Cometriq (cabozantinib) resulted in an improved median progression-free survival of 4.3 months, compared to 1.8 months with Tarceva (erlotinib), and an improved median overall survival of 9.2 months, versus 5.1 with Tarceva (erlotinib), in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 7519,
                    "pubMedId": 27825638,
                    "title": "Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27825638"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4776,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and inhibition of downstream targets, including Cbl, in EGFR wild-type expressing compared to EGFR L858R expressing transformed cells in culture (PMID: 25573954).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4727,
                    "pubMedId": 25573954,
                    "title": "Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25573954"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4778,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and resulted in decreased inhibition of downstream targets, including Stat5, in transformed cells expressing wild-type EGFR, compared to EGFR L858R expressing cells in culture (PMID: 25573954).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4727,
                    "pubMedId": 25573954,
                    "title": "Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25573954"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3938,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment demonstrated reduced potency inhibiting proliferation of non-small cell lung carcinoma cell lines harboring wild-type EGFR in culture (PMID: 26090892).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7255,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 4428,
                "therapyName": "Gefitinib + K-756",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6261,
                    "pubMedId": 27196752,
                    "title": "The Discovery and Characterization of K-756, a Novel Wnt/\u03b2-Catenin Pathway Inhibitor Targeting Tankyrase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196752"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1229,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Nexavar (sorafenib) demonstrated efficacy in NSCLC patients with wild-type EGFR (PMID: 24166906).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 244,
                    "pubMedId": 24166906,
                    "title": "Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24166906"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12878,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, compared to Taxotere (docetaxel), treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in EGFR wild-type (HR=0.67, P<0.001) but not EGFR mutant (HR=1.11, P=0.54) non-small cell lung carcinoma patients, and there was a statistically significant treatment-EGFR mutation interaction (p=0.005) (PMID: 29270615).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10827,
                    "pubMedId": 29270615,
                    "title": "Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29270615"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1088,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combined treatment of DNA methyltransferase inhibitor decitabine and EGFR inhibitor gefitinib on EGFR wild-type colon cancer cell lines resulted in synergistic effects in inhibiting cell growth and migration (PMID: 24874286).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 1531,
                "therapyName": "Decitabine + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 822,
                    "pubMedId": 24874286,
                    "title": "Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24874286"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8040,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 4625,
                "therapyName": "Cisplatin + ER2",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5133,
                    "pubMedId": 27040853,
                    "title": "ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27040853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3299,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, EGFR wild-type non-small cell lung cancer patients treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a clinical benefit as indicated by a disease control rate of 43% (15/43), thus, exceeding the primary endpoint rate of 20% (PMID: 26106072).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 1097,
                "therapyName": "Erlotinib + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3719,
                    "pubMedId": 26106072,
                    "title": "Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26106072"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5646,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ER2 inhibited EGFR signaling and proliferation and induced apoptosis of EGFR wild-type non-small cell lung cancer cells in culture and delayed tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 3916,
                "therapyName": "ER2",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5133,
                    "pubMedId": 27040853,
                    "title": "ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27040853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8232,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tarceva (erlotinib) and Ganetespib led to tumor regression in cell line xenograft models of EGFR wild-type non-small cell lung cancer, and demonstrated improved efficacy over either agent alone (PMID: 25077897).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 2802,
                "therapyName": "Erlotinib + Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2971,
                    "pubMedId": 25077897,
                    "title": "The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25077897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1217,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase II and III clinical trials, Chinese patients with advanced NSCLC have shown icotinib to be safe and effective, with indication that patients with wild-type EGFR may receive some benefit (PMID: 23372346, PMID: 23948351, PMID: 24438614, PMID: 25261231).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 75,
                    "pubMedId": 23372346,
                    "title": "Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23372346"
                },
                {
                    "id": 98,
                    "pubMedId": 24438614,
                    "title": "Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24438614"
                },
                {
                    "id": 956,
                    "pubMedId": 25261231,
                    "title": "A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261231"
                },
                {
                    "id": 17992,
                    "pubMedId": 23948351,
                    "title": "Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948351"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8044,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) did not inhibit Egfr signaling or survival of patient-derived EGFR wild-type glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6540,
                    "pubMedId": 25939761,
                    "title": "Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9239,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) did not inhibit growth of lung carcinoma cells with activated wild-type EGFR signaling via EGF stimulation in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9741,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Cometriq (cabozantinib) and Tarceva (erlotinib) resulted in an improved median progression-free survival of 4.7 mo vs. 1.8 mo with Tarceva (erlotinib) alone, and an improved median overall survival of 13.3 months vs 5.1 mo with Tarceva (erlotinib) in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 1255,
                "therapyName": "Cabozantinib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 7519,
                    "pubMedId": 27825638,
                    "title": "Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27825638"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9117,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Abivertinib (AC0010) resulted in no antitumor activity when treating a squamous cell carcinoma cell line xenograft model harboring wild-type EGFR (PMID: 27573423).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Abivertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1749,
                "name": "squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6924,
                    "pubMedId": 27573423,
                    "title": "AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27573423"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, postoperative adjuvant Iressa (gefitinib) did not provide prolonged disease-free survival nor increased overall survival in NSCLC patients with wild-type EGFR (PMID: 23980091).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 241,
                    "pubMedId": 23980091,
                    "title": "Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23980091"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6991,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 induced tumor regression in a patient-derived xenograft model of glioblastoma multiforme harboring amplified wild-type EGFR and EGFR vIII (exon 2-7 deletion) (PMID: 26846818).",
            "molecularProfile": {
                "id": 24172,
                "profileName": "EGFR act mut EGFR amp EGFR wild-type"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7065,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 29% (5/17) of EGFR wild-type, MET over-expressing non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",
            "molecularProfile": {
                "id": 24382,
                "profileName": "EGFR wild-type MET over exp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6064,
                    "pubMedId": null,
                    "title": "Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).",
                    "url": "http://meetinglibrary.asco.org/content/165406-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8231,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).",
            "molecularProfile": {
                "id": 26202,
                "profileName": "BRAF G466V EGFR wild-type"
            },
            "therapy": {
                "id": 745,
                "therapyName": "Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2971,
                    "pubMedId": 25077897,
                    "title": "The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25077897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9257,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung cancer cell line harboring EGFR wild-type and decreased expression of PAK1 demonstrated sensitivity to Iressa (gefitinib) in culture, resulting in decreased cell viability (PMID: 27178741).",
            "molecularProfile": {
                "id": 26794,
                "profileName": "EGFR wild-type PAK1 dec exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9256,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung papillary adenocarcinoma cell line harboring EGFR wild-type and expressing PAK1 demonstrated resistance to Iressa (gefitinib) in culture (PMID: 27178741).",
            "molecularProfile": {
                "id": 26797,
                "profileName": "EGFR wild-type PAK1 pos"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5588,
                "name": "lung papillary adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14987,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).",
            "molecularProfile": {
                "id": 30444,
                "profileName": "ALK wild-type EGFR wild-type"
            },
            "therapy": {
                "id": 6798,
                "therapyName": "Cisplatin + Pembrolizumab + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11953,
                    "pubMedId": 29658856,
                    "title": "Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29658856"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14986,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small-cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).",
            "molecularProfile": {
                "id": 30444,
                "profileName": "ALK wild-type EGFR wild-type"
            },
            "therapy": {
                "id": 2105,
                "therapyName": "Carboplatin + Pembrolizumab + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11953,
                    "pubMedId": 29658856,
                    "title": "Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29658856"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19421,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (IMpower130) that supported FDA approval, Tecentriq (atezolizumab) in combination with carboplatin and nab-paclitaxel resulted in significantly improved median overall survival (18.6 vs 13.9 months, HR=0.79, p=0.033) and median progression-free survival (7.0 vs 5.5 months, HR=0.64, p<0.0001) compared to chemotherapy in patients with stage IV non-squamous non-small-cell lung cancer harboring no ALK or EGFR mutations (PMID: 31122901; NCT02367781).",
            "molecularProfile": {
                "id": 30444,
                "profileName": "ALK wild-type EGFR wild-type"
            },
            "therapy": {
                "id": 3946,
                "therapyName": "Atezolizumab + Carboplatin + Nab-paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15451,
                    "pubMedId": null,
                    "title": "Tecentriq (atezolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761034"
                },
                {
                    "id": 17012,
                    "pubMedId": 31122901,
                    "title": "Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31122901"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15394,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (IMpower150) that supported FDA approval, Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin resulted in significantly improved median progression-free survival (8.3 vs 6.8 months, HR=0.62, p<0.001) and median overall survival (19.2 vs 14.7 months, HR=0.78, p=0.02) compared to control in patients with metastatic nonsquamous non-small cell lung cancer, regardless of PD-L1 expression and EGFR or ALK mutation status (PMID: 29863955; NCT02366143).",
            "molecularProfile": {
                "id": 30444,
                "profileName": "ALK wild-type EGFR wild-type"
            },
            "therapy": {
                "id": 2370,
                "therapyName": "Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13139,
                    "pubMedId": 29863955,
                    "title": "Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29863955"
                },
                {
                    "id": 15451,
                    "pubMedId": null,
                    "title": "Tecentriq (atezolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761034"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15163,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Opdivo (nivolumab)-treated non-small cell lung cancer patients compared to STK11 or EGFR-mutant cohorts (p=0.03) (PMID: 29764856).",
            "molecularProfile": {
                "id": 30811,
                "profileName": "EGFR wild-type STK11 wild-type TP53 mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12766,
                    "pubMedId": 29764856,
                    "title": "TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29764856"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15162,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Keytruda (pembrolizumab)-treated non-small cell lung cancer patients (PMID: 29764856).",
            "molecularProfile": {
                "id": 30811,
                "profileName": "EGFR wild-type STK11 wild-type TP53 mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12766,
                    "pubMedId": 29764856,
                    "title": "TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29764856"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16742,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-042) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in significantly improved overall survival compared to chemotherapy in all three TPS populations (50% or greater, HR=0\u00b769, p=0\u00b70003; 20% or greater, HR=0\u00b777, p=0\u00b70020, and 1% or greater, HR=0\u00b781, p=0\u00b70018) of untreated advanced non-small cell lung cancer patients with no sensitizing EGFR mutations or ALK rearrangement (PMID: 30955977; NCT02220894).",
            "molecularProfile": {
                "id": 31323,
                "profileName": "ALK wild-type CD274 pos EGFR wild-type"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14784,
                    "pubMedId": 30955977,
                    "title": "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30955977"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15940,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-024) that supported FDA approval, treatment with Keytruda (pembrolizumab) improved progression-free survival (10.3 vs 6.0 months, HR=0.50, p<0.001) and estimated 6-month overall survival rate (80.2% vs 72.4%, HR=0.60, p<0.001) compared to chemotherapy in untreated advanced non-small cell lung cancer patients with CD274 (PD-L1) expression on over 50% of tumor cells, and with no EGFR activating mutations or ALK rearrangement (PMID: 27718847; NCT02142738).",
            "molecularProfile": {
                "id": 31323,
                "profileName": "ALK wild-type CD274 pos EGFR wild-type"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14049,
                    "pubMedId": 27718847,
                    "title": "Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27718847"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17460,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with advanced non-small cell lung cancer with PD-L1 (CD274) expression of at least 50% and negative testing for ALK, BRAF, EGFR, and ROS1 (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 32621,
                "profileName": "ALK wild-type BRAF wild-type CD274 pos EGFR wild-type ROS1 wild-type"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20323,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited tumor growth by 78% in a cell line xenograft model of non-small cell lung cancer harboring KRAS G12S and wild-type EGFR, and inhibited tumor growth by 75% in models developed Tarceva (erlotinib) resistance (PMID: 19447865)",
            "molecularProfile": {
                "id": 35102,
                "profileName": "EGFR wild-type KRAS G12S"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11395,
                    "pubMedId": 19447865,
                    "title": "Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19447865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20324,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment inhibited tumor growth by 85% in a cell line xenograft model of non-small cell lung cancer harboring KRAS G12S and wild-type EGFR, and inhibited tumor growth by 58% in models developed Tarceva (erlotinib) resistance (PMID: 19447865).",
            "molecularProfile": {
                "id": 35102,
                "profileName": "EGFR wild-type KRAS G12S"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11395,
                    "pubMedId": 19447865,
                    "title": "Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19447865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 343,
            "profileName": "EGFR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17705,
            "profileName": "EGFR wild-type MET wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24172,
            "profileName": "EGFR act mut EGFR amp EGFR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24382,
            "profileName": "EGFR wild-type MET over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26202,
            "profileName": "BRAF G466V EGFR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26794,
            "profileName": "EGFR wild-type PAK1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26797,
            "profileName": "EGFR wild-type PAK1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30444,
            "profileName": "ALK wild-type EGFR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30811,
            "profileName": "EGFR wild-type STK11 wild-type TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31323,
            "profileName": "ALK wild-type CD274 pos EGFR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32621,
            "profileName": "ALK wild-type BRAF wild-type CD274 pos EGFR wild-type ROS1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35102,
            "profileName": "EGFR wild-type KRAS G12S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}